Literature DB >> 31147790

Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer.

Lianyuan Tao1,2, Juntuo Zhou3, Chunhui Yuan2, Lingfu Zhang2, Deyu Li1, Dandan Si4, Dianrong Xiu5, Lijun Zhong6.   

Abstract

INTRODUCTION: Pancreatic cancer (PC) is one of the most aggressive malignancies, and it's difficult to diagnosis PC at an early stage, which leads to the poor prognosis of PC.
OBJECTIVES: To identifiy the possible prognosis or dignosis metabolite biomarkers in the serum exosome of PC patients.
METHODS: We employed LC-DDA-MS based untargeted lipidomic analysis to search for potential candidate biomarkers in the serum exosome of PC patients. Then LC-MRM-MS based targeted lipid quantification was used to validate the trends of the candidate biomarkers in larger sample cohorts.
RESULTS: About 270 lipids belonging to 20 lipid species were found significantly dysregulated between the serum exosome of PC patients and healthy controls. 61 of them were validated in larger samples size. We further analysis the correlation between these dysregulated lipids and other PC related factors, and results show that LysoPC 22:0, PC (P-14:0/22:2) and PE (16:0/18:1) are all associated with tumor stage, CA19-9, CA242 and tumor diameter. What's more, PE (16:0/18:1) is also found to be significantly correlated with the patient's overall survival.
CONCLUSION: These data reveal dysregulated lipids in serum exosome of PC patients, which have potential to be biomarkers for diagnosis, or unveil pathological relationship between exosome and PC progress.

Entities:  

Keywords:  Exosome biomarker; Lipidomics; Pancreatic cancer; Serum exosome

Mesh:

Substances:

Year:  2019        PMID: 31147790     DOI: 10.1007/s11306-019-1550-1

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  27 in total

1.  Effects of glaucocalyxin A on human liver cancer cells as revealed by GC/MS- and LC/MS-based metabolic profiling.

Authors:  Yue Liu; Shan Lu; Liang Zhao; Xin Dong; Zhenyu Zhu; Yongsheng Jin; Haisheng Chen; Feng Lu; Zhanying Hong; Yifeng Chai
Journal:  Anal Bioanal Chem       Date:  2018-04-13       Impact factor: 4.142

Review 2.  Challenges of Pancreatic Cancer.

Authors:  Julien Dimastromatteo; Jacob L Houghton; Jason S Lewis; Kimberly A Kelly
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

Review 3.  Strategies for large-scale targeted metabolomics quantification by liquid chromatography-mass spectrometry.

Authors:  Juntuo Zhou; Yuxin Yin
Journal:  Analyst       Date:  2016-11-14       Impact factor: 4.616

4.  The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.

Authors:  Xinchun Zhou; Thomas J Lawrence; Zhi He; Charles R Pound; Jinghe Mao; Steven A Bigler
Journal:  Exp Mol Pathol       Date:  2011-11-11       Impact factor: 3.362

5.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

Review 6.  Biomarkers in pancreatic adenocarcinoma: current perspectives.

Authors:  Douglas S Swords; Matthew A Firpo; Courtney L Scaife; Sean J Mulvihill
Journal:  Onco Targets Ther       Date:  2016-12-09       Impact factor: 4.147

Review 7.  Biomarkers and Targeted Therapy in Pancreatic Cancer.

Authors:  Fataneh Karandish; Sanku Mallik
Journal:  Biomark Cancer       Date:  2016-04-26

8.  Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study.

Authors:  Tilman Kühn; Anna Floegel; Disorn Sookthai; Theron Johnson; Ulrike Rolle-Kampczyk; Wolfgang Otto; Martin von Bergen; Heiner Boeing; Rudolf Kaaks
Journal:  BMC Med       Date:  2016-01-28       Impact factor: 8.775

9.  Comparative metabolic and lipidomic profiling of human breast cancer cells with different metastatic potentials.

Authors:  Hye-Youn Kim; Kyung-Min Lee; So-Hyun Kim; Yeo-Jung Kwon; Young-Jin Chun; Hyung-Kyoon Choi
Journal:  Oncotarget       Date:  2016-10-11

Review 10.  Exosomes in cancer development and clinical applications.

Authors:  Yu-Ling Tai; Ko-Chien Chen; Jer-Tsong Hsieh; Tang-Long Shen
Journal:  Cancer Sci       Date:  2018-07-13       Impact factor: 6.716

View more
  30 in total

1.  Applications of Lipidomics in Tumor Diagnosis and Therapy.

Authors:  Yuping Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Femtoliter Injection of ESCRT-III Proteins into Adhered Giant Unilamellar Vesicles.

Authors:  Vasil N Georgiev; Yunuen Avalos-Padilla; Xavier Fernàndez-Busquets; Rumiana Dimova
Journal:  Bio Protoc       Date:  2022-02-20

Review 3.  Extracellular vesicles and particles impact the systemic landscape of cancer.

Authors:  Serena Lucotti; Candia M Kenific; Haiying Zhang; David Lyden
Journal:  EMBO J       Date:  2022-09-02       Impact factor: 14.012

4.  Mycobacterium tuberculosis Affects Protein and Lipid Content of Circulating Exosomes in Infected Patients Depending on Tuberculosis Disease State.

Authors:  Fantahun Biadglegne; Johannes R Schmidt; Kathrin M Engel; Jörg Lehmann; Robert T Lehmann; Anja Reinert; Brigitte König; Jürgen Schiller; Stefan Kalkhof; Ulrich Sack
Journal:  Biomedicines       Date:  2022-03-27

Review 5.  Small extracellular vesicles in cancer.

Authors:  Komal Abhange; Amy Makler; Yi Wen; Natasha Ramnauth; Wenjun Mao; Waseem Asghar; Yuan Wan
Journal:  Bioact Mater       Date:  2021-04-07

6.  Molecular signatures of tumor progression in pancreatic adenocarcinoma identified by energy metabolism characteristics.

Authors:  Cong Tan; Xin Wang; Xu Wang; Weiwei Weng; Shu-Juan Ni; Meng Zhang; Hesheng Jiang; Lei Wang; Dan Huang; Weiqi Sheng; Mi-Die Xu
Journal:  BMC Cancer       Date:  2022-04-13       Impact factor: 4.430

7.  Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.

Authors:  Ariadna Martín-Blázquez; Cristina Jiménez-Luna; Caridad Díaz; Joaquina Martínez-Galán; Jose Prados; Francisca Vicente; Consolación Melguizo; Olga Genilloud; José Pérez Del Palacio; Octavio Caba
Journal:  Cancers (Basel)       Date:  2020-04-18       Impact factor: 6.639

Review 8.  From tumor microenvironment communicants to biomarker discovery: Selectively packaged extracellular vesicular cargoes in pancreatic cancer.

Authors:  Song Han; Patrick Underwood; Steven J Hughes
Journal:  Cytokine Growth Factor Rev       Date:  2020-01-11       Impact factor: 7.638

9.  Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-l-Carnitine as Potential Predictive Indicators of Gemcitabine Efficacy in Pancreatic Cancer Patients.

Authors:  Dongyuan Wu; Xinyuan Li; Xiaohan Zhang; Fang Han; Xin Lu; Lei Liu; Junsheng Zhang; Mei Dong; Huanjie Yang; Hui Li
Journal:  Front Oncol       Date:  2020-01-29       Impact factor: 6.244

10.  Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis.

Authors:  Lingling Wan; Qingyi Liu; Di Liang; Yongdong Guo; Guangjie Liu; Jinxia Ren; Yutong He; Baoen Shan
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.